Board of Directors

Lou Panaccio


Mr Panaccio, a successful healthcare businessman with extensive experience progressing companies from concept to commercialisation, was appointed to the role of Chairman of the Board, effective from 1 July 2014. Mr Panaccio possesses more than 30 years’ executive leadership experience in healthcare services and life sciences, including approximately 15 years’ board-level experience. Mr Panaccio is currently a Non-Executive Director of ASX50 company and one of the world’s largest medical diagnostics companies, Sonic Healthcare Limited, where he has served since 2005. In addition to his Sonic Healthcare Limited role, Mr Panaccio is the Executive Chairman of Health Networks Australia Group, Non-Executive Director Yarra Community Housing, Non-Executive Chairman of Urban Communities Limited and Non-Executive Chairman of Genera Biosystems Limited. Mr Panaccio has also served in executive and board roles with Melbourne Pathology Group, Monash IVF Group, Primelife Corporation Limited and other private entities. During the past three years Mr Panaccio has also served as a Director of the following other listed companies:

  • Genera Biosystems  (appointed 25 November 2010)
  • Sonic Healthcare Limited  (appointed June 2005)

Jeremy Curnock Cook

(Non-Executive Director)

Mr Curnock Cook was appointed to the Board on 19 October 2012 and is currently on a number of boards of International Healthcare and Biotechnology companies. He is the former head of the life science private equity team at Rothschild Asset Management, was responsible for the launch of the first dedicated biotechnology fund for the Australian market and the conception and launch of the International Biotechnology Trust. He is currently the Managing Director of Bioscience Managers Pty Ltd, responsible for the BM Asia Pacific Heathcare Fund. During the past three years Mr Curnock Cook has also served as a director of the following other listed companies:

  • BioScience Managers Pty Ltd (Appointed 18 August 2017)
  • SummatiX Ltd (Appointed 27 July 2017)
  • Adherium Ltd (Appointed July 2015)
  • SmartMatrix Ltd (Appointed 6 Feb 2013)
  • Sea Dragon Marine Oils Ltd (Appointed 15 October 2012)
  • Phylogica Ltd (Appointed March 2012)
  • Rex Bionics plc* (Appointed 27 February 2012)
  • International BioScience Managers Ltd (Appointed 2 March 2000)
  • AmpliPhi Bioscience Corporation Inc (Appointed July 1995)

Dr Michael Perry

(Non-Executive Director)

Dr. Perry was appointed as CEO on 2 June 2017, after serving on the Board since 6 February 2013. From 2014 – 2017, Dr. Perry served as Chief Scientific Officer of Novartis’ Cell and Gene Therapy Unit. and from 2012 – 2014 he served as Vice President and Global Head of Stem Cell Therapy for Novartis Pharmaceuticals Corp, a US affiliate of Switzerland-based Novartis AG. Dr. Perry, based in the United States, has previously served as the Global Head of R&D at Baxter Healthcare, President and CEO of Cell & Gene Therapy at Novartis affiliates Systemix Inc. and Genetic Therapy, Inc., VP Regulatory Affairs at Sandoz Pharmaceuticals Corp., Director of Regulatory Affairs at Schering-Plough Corporation, and Chairman, CEO or CMO at several early stage biotech companies. He also previously served as a Venture Partner with Bay City Capital, LLC based in San Francisco California. During the past three years Dr. Perry has also served as a Director of the following other listed companies:

Arrowhead Pharmaceuticals  (Appointed December 2011)

Louis Drapeau

(Non-Executive Director)

Mr Louis Drapeau was appointed to the board on 13 January 2016 and brings considerable expertise in both the biotech sector and the financial rigour required of US public companies. Based in the US, Mr Drapeau is an Independent Director at AmphliPhi Biosciences Corporation (NYSE), CFO, Principal Accounting Officer and Vice President at Insite Vision Inc., and Independent Director at Bio-Rad Laboratories, Inc. (NYSE). Mr Drapeau has held senior positions with Nektar Therapeutics and BioMarin Pharmaceutical, Inc., and has been an Audit Partner at Arthur Andersen LLP. Mr Drapeau has formally been an Independent Director at InterMune, Inc. (NASDAQ), Bionovo, Inc. (NASDAQ), and Inflazyme Pharmaceuticals Ltd (TSE). He has an MBA from Stanford University.

Damien McDonald

(Non-Executive Director)

Mr Damien McDonald was appointed to the board on 13 January 2016 and has a proven track record of achieving value in the medical device space. Mr McDonald is the Chief Executive Officer of LivaNova, a NASDAQ listed Medtech innovator. Previously, Mr. McDonald served as Chief Operating Officer of LivaNova. Prior to that, he was Group Executive and Corporate Vice President at Danaher Corporation where he led a $1.5billion group of dental consumables companies. Earlier in his tenure, he was Group President of Kerr where he and his team focused on building a strong research and development pipeline while improving operational performance utilizing the Danaher Business System. Additionally, Mr. McDonald previously led Zimmer’s spine division where he demonstrated his leadership skills, attracting a strong executive team that created a growth trajectory for the business unit. Earlier in his career, he worked with J&J’s Medical Device Franchises, including Ethicon, where he led marketing of the $2.5billion medical device unit. Mr. McDonald earned an MBA at the Institute for Management Development (IMD) in Lausanne, Switzerland, along with a Master of Science in International Economics from the University of Wales, U.K. He also holds a Bachelor of Economics degree and Bachelor of Pharmacy degree, both from the University of Queensland, Australia.

Professor Suzanne Crowe

(Non-Executive Director)

Professor Suzanne Crowe AM was appointed to the board on 13 January 2016. Australian-based, she is a physician-scientist and company director with extensive expertise in supporting companies with their medical and scientific strategies. Prof Crowe is an Associate Director of the Burnet Institute, and is a Principal Research Fellow of the Australian National Health and Medical Research Council. She is a Principal Specialist in Infectious Diseases at The Alfred Hospital, Melbourne and Adjunct Professor of Medicine and Infectious Diseases at Monash University, Melbourne, and has published more than 200 peer-reviewed papers. Prof Crowe is a member of the Australian Institute of Company Directors, and is a Director of St Vincents Health Australia. Prof Crowe was appointed as a Member of the Order of Australia (AM) in 2011 to recognise her service to medical research in HIV/AIDS. She has medical and MD degrees from Monash University, an internal medicine specialist qualification in Infectious Diseases from the Royal Australasian College of Physicians, and a Diploma in Medical Laboratory Technology from the Royal Melbourne Institute of Technology.